<DOC>
	<DOCNO>NCT00005822</DOCNO>
	<brief_summary>RATIONALE : SU5416 may stop growth breast cancer stop blood flow tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining SU5416 chemotherapy may kill cancer cell . PURPOSE : Phase I trial study effectiveness combine SU5416 doxorubicin treat patient stage IIIB stage IV inflammatory breast cancer .</brief_summary>
	<brief_title>SU5416 Doxorubicin Treating Patients With Stage IIIB Stage IV Inflammatory Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose SU5416 doxorubicin patient stage IIIB IV inflammatory breast cancer . - Determine overall response , response rate , progression-free survival rate patient treat regimen . - Determine antiangiogenic effect regimen patient . - Assess relationship plasma level drug safety efficacy patient . OUTLINE : This dose-escalation study . Patients receive doxorubicin IV continuously 72 hour day 1-3 course 1 . For subsequent course , patient receive doxorubicin course 1 SU5416 IV 1 hour twice weekly ( day 1 4 ) begin week 2 course 2 . Treatment repeat every 21 day 5 course absence disease progression unacceptable toxicity . After chemotherapy , patient undergo modified radical mastectomy radiotherapy chest wall regional lymph node . Patients estrogen progesterone receptor positive disease receive oral tamoxifen 5 year radiotherapy . Cohorts 3-6 patient receive escalate dos SU5416 doxorubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 3 patient may treat dose level . Patients follow every 3 month disease progression . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 6-9 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIB IV ( supraclavicular lymph node involvement metastasis ) inflammatory breast cancer Primary secondary No brain metastasis primary brain tumor Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 9.0 g/dL Hepatic : Bilirubin normal AST ALT less 2 time upper limit normal PT PTT normal OR INR le 1.1 Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : LVEF least 50 % MUGA No New York Heart Association class III IV heart disease No uncompensated coronary artery disease No myocardial infarction unstable angina within past 6 month No deep venous arterial thrombosis within past 3 month Pulmonary : No history pulmonary embolism within past 3 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history diabetes mellitus severe peripheral vascular disease No prior concurrent malignancy within past 10 year except inactive nonmelanomatous skin cancer carcinoma situ cervix No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent epoetin alfa filgrastim ( GCSF ) Chemotherapy : No 2 prior chemotherapy regimen allow No prior doxorubicin anthracycline Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>